NCT01709292 2026-04-16
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
93 trialsNCT03048279 2026-04-16
Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2
M.D. Anderson Cancer Center
Active not recruiting
NCT03110978 2026-04-16
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07534371 2026-04-16
Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study
West China Hospital
Active not recruiting
NCT05470595 2026-04-15
LCNEC-ALPINE
Technische Universität Dresden
Phase 2 Active not recruiting
NCT04948437 2026-04-13
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
National Taiwan University Hospital
Active not recruiting
NCT05249114 2026-04-13
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Providence Health & Services
Phase 1 Active not recruiting
NCT04291885 2026-04-09
I-MAT
Melanoma and Skin Cancer Trials Limited
Phase 2 Active not recruiting
NCT05696548 2026-04-09
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
National Cancer Center Hospital East
Phase 2 Active not recruiting
NCT02673333 2026-04-06
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04412629 2026-04-06
Cabozantinib in High Grade Neuroendocrine Neoplasms
Washington University School of Medicine
Phase 2 Active not recruiting
NCT04261855 2026-03-27
GoTHAM
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Active not recruiting
NCT04804371 2026-03-23
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
University Health Network, Toronto
Phase NA Active not recruiting
NCT03950609 2026-03-19
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03665064 2026-03-16
Long Term Outcome Study in Patients With Pituitary Disorders
University of Alberta
Active not recruiting
NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04175678 2026-03-10
Project 1: Diet and Exercise Modulate the Sperm Epigenome in Men
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Phase NA Active not recruiting
NCT04810091 2026-03-09
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT06448208 2026-03-09
Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Active not recruiting
NCT07446036 2026-03-03
Prediction Model for Postoperative Headache After Transsphenoidal Pituitary Surgery
Beijing Tiantan Hospital
Active not recruiting
NCT03839498 2026-03-02
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
Columbia University
Phase 2 Active not recruiting
NCT03946527 2026-03-02
LAMPARA
Columbia University
Phase 2 Active not recruiting
NCT04321954 2026-02-27
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
Massachusetts Eye and Ear Infirmary
Phase 2 Active not recruiting
NCT04969887 2026-02-27
MOST-CIRCUIT
Olivia Newton-John Cancer Research Institute
Phase 2 Active not recruiting
NCT03416686 2026-02-25
METATHYRAF
Assistance Publique - Hôpitaux de Paris
Phase NA Active not recruiting
NCT04675710 2026-02-19
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04993261 2026-02-19
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT04171622 2026-02-17
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04848337 2026-02-12
PLANE-PC
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT02143726 2026-02-11
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT04459273 2026-02-05
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02721732 2026-01-29
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03333616 2026-01-21
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03891784 2026-01-14
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
University of Washington
Phase 2 Active not recruiting
NCT06232564 2026-01-14
PELICAN
Imperial College London
Phase 2 Active not recruiting
NCT05735912 2026-01-13
ERASIN-RCT
Azienda Ospedaliera Universitaria Integrata Verona
Phase NA Active not recruiting
NCT03181100 2026-01-09
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06936813 2026-01-08
The PROMISE Survey
University Hospital, Basel, Switzerland
Active not recruiting
NCT03465618 2026-01-07
A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04813042 2025-12-24
WOD
Murdoch Childrens Research Institute
Phase NA Active not recruiting
NCT03728361 2025-12-18
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05064150 2025-12-18
NET-PRO
University of Iowa
Active not recruiting
NCT04701307 2025-12-15
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02743741 2025-12-03
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
University Health Network, Toronto
Phase NA Active not recruiting
NCT03541720 2025-12-03
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
St. Jude Children's Research Hospital
Phase EARLY_PHASE1 Active not recruiting
NCT06100367 2025-12-02
11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours
Changi General Hospital
Phase 2/3 Active not recruiting
NCT04624477 2025-11-28
Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer
University Health Network, Toronto
Active not recruiting
NCT03271892 2025-11-26
AS-PTC
University Health Network, Toronto
Active not recruiting
NCT03449108 2025-11-21
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04530916 2025-11-17
WB2020
Colorado State University
Phase 1/2 Active not recruiting